SCHEMBL5653055

SCHEMBL5653055

COc1ccccc1C(C)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
ACHE P22303 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.45
POLB P06746 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALDH1A1 P00352 2/20 0.45
SGMS2 Q8NHU3 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HTR1A P08908 2/20 0.44
ADRA1D P25100 2/20 0.44
ADRA1A P35348 2/20 0.44
ADRA1B P35368 2/20 0.44
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ABCB1 P08183 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4596542 0.83 CA1 (0.45) CA1CA2ACHEL3MBTL1POLB
SCHEMBL1825221 0.81 CA1 (0.41) CA1CA2ACHEL3MBTL1SGMS2
SCHEMBL22824152 0.79 CA1 (0.46) CA1CA2ACHEL3MBTL1POLB
SCHEMBL14667612 0.79 CA1 (0.41) CA1CA2ACHEL3MBTL1POLB
SCHEMBL1825970 0.79 ALDH1A1 (0.43) CA1CA2ACHEL3MBTL1HTT
SCHEMBL4944038 0.78 CA1 (0.43) CA1CA2ACHEL3MBTL1POLB
SCHEMBL13553366 0.76 CA1 (0.43) CA1CA2ACHEL3MBTL1POLB
SCHEMBL14376093 0.76 CASP1 (0.46) ALDH1A1CYP2C19LMNAGAACASR
SCHEMBL11856073 0.76 SRC (0.42) HTTALDH1A1CYP2D6CYP2C19MAPT
SCHEMBL8580049 0.76 HTR1A (0.39) CA1CA2L3MBTL1ALDH1A1SGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250432-B2 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-31 US disclosed
WO-2006126751-A1 NEW DIARYL-ISOXAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME FOR THE PREVENTION AND THE TREATMENT OF CANCERS KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2006-11-30 WO disclosed
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers UACA, SQLE, ALDH1A2 CA1 1209/4885CA2 841/4885ACHE 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.